Mabthera 1400mg, 1600mg (SC) Rituximab

MabThera SC is a subcutaneous formulation of Ristova that contains hyaluronidase, which temporarily and reversibly degrades hyaluronan, a gel-like substance that forms a barrier between cells under the skin. This enables the subcutaneous formulation of Ristova to be rapidly dispersed and absorbed over a greater area.

MabThera SC is approved for the treatment of adults with the following blood cancers: previously untreated and relapsed/refractory follicular lymphoma, non-progressing (including stable disease) follicular lymphoma, and previously untreated diffuse large B-cell lymphoma.

Full prescribing information is available on request.
If you have a scientific query related to one of Roche's products, please contact us at [email protected]
In case of any adverse events or safety queries, please contact [email protected]